OPTION CARE INC/DE Form 10-Q November 09, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2005

OR

• TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

to

Commission file number 0-19878

OPTION CARE, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

485 Half Day Road, Suite 300 Buffalo Grove, Illinois (Address of principal executive office) **36-3791193** (IRS Employer Identification No.)

60089 (zip code)

(847) 465-2100 (Registrant s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes \acute{y} No o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ý No o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ý

Indicate the number of shares outstanding of each of the issuer s classes of common stock, as of the latest practicable date.

Class

Issued and Outstanding as of November 1, 2005

Common Stock - \$0.01 par value

32,765,262

INDEX

OPTION CARE, INC. AND SUBSIDIARIES

PART I	FINANCIAL INFORMATION
<u>Item 1.</u>	Financial Statements (Unaudited)
	Condensed consolidated balance sheets September 30, 2005 and December 31, 2004
	Condensed consolidated statements of income Three and nine months ended September 30, 2005 and 2004
	Condensed consolidated statements of cash flows Nine months ended September 30, 2005 and 2004
	Notes to condensed consolidated financial statements September 30, 2005
<u>Item 2.</u>	Management s Discussion and Analysis of Financial Condition and Results of Operations
<u>Item 3.</u>	Quantitative and Qualitative Disclosures about Market Risk
<u>Item 4.</u>	Controls and Procedures
PART II	OTHER INFORMATION
<u>Item 1.</u>	Legal Proceedings
<u>Item 2.</u>	Unregistered Sales of Equity Securities and Use of Proceeds
<u>Item 3.</u>	Defaults Upon Senior Securities
<u>Item 4.</u>	Submission of Matters to a Vote of Security Holders
<u>Item 5.</u>	Other Information
<u>Item 6.</u>	<u>Exhibits</u>
<u>SIGNATURES</u>	

2

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Option Care, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except per share amounts)

	mber 30, 2005 (naudited)	December 31, 2004 (Note 1)		
Assets				
Current assets:				
Cash and cash equivalents	\$ 10,107	\$	19,816	
Short-term investments	53,644		75,370	
Accounts receivable, net	73,744		69,930	
Inventory	11,917		13,191	
Deferred income tax benefit	2,894		3,098	
Other current assets	8,995		5,459	
Total current assets	161,301		186,864	
Equipment and other fixed assets, net	18,677		13,709	
Goodwill, net	106,507		65,356	
Other assets	5,401		3,918	
Total assets	\$ 291,886	\$	269,847	
Liabilities and stockholders equity				
Current liabilities:				
Trade accounts payable	\$	\$	21,819	
Current portion of long-term debt	47		19	
Other current liabilities	7,015		6,573	
Total current liabilities	25,266		28,411	
Long-term debt, less current portion	86,319		86,306	
Deferred income tax liability	8,645		7,468	
Other liabilities	600		551	
Minority interest	634		548	
Total liabilities	121,464		123,284	
Stockholders equity:				
Common stock, \$.01 par value per share, 60,000 shares authorized, 32,708 and 22,182 shares issued and autstanding at Sentember 20, 2005 and December 21				
32,183 shares issued and outstanding at September 30, 2005 and December 31, 2004, respectively	327		322	
Common stock to be issued, 228 and 171 shares at September 30, 2005 and				
December 31, 2004, respectively	1,831		1,085	
Additional paid-in capital	112,326		108,062	
Retained earnings	55,938		41,612	

Less treasury stock, at cost, 474 shares at December 31, 2004		(4,518)
Total stockholders equity	170,422	146,563
Total liabilities and stockholders equity	\$ 291,886 \$	269,847

See notes to condensed consolidated financial statements

Option Care, Inc. and Subsidiaries

Condensed Consolidated Statements of Income

(Unaudited)

(in thousands, except per share amounts)

	Three months ended September 30,			Nine mon Septem	ed	
	2005		2004	2005		2004
Revenue:						
Specialty pharmacy services	\$ 67,239	\$	57,752 \$	209,736	\$	181,091
Infusion and related healthcare services	51,178		39,405	141,716		111,801
Other	3,476		2,794	10,687		8,859
Total revenue	121,893		99,951	362,139		301,751
Cost of revenue:						
Cost of goods sold	71,680		59,153	219,122		181,958
Cost of services provided	13,688		10,870	38,269		32,130
Total cost of revenue	85,368		70,023	257,391		214,088
Gross profit	36,525		29,928	104,748		87,663
Selling, general and administrative expenses	24,689		19,787	69,739		58,236
Provision for doubtful accounts	2,248		1,601	6,727		4,622
Depreciation and amortization	915		724	2,668		1,974
Total operating expenses	27,852		22,112	79,134		64,832
Operating income	8,673		7,816	25,614		22,831
Interest income, net	108		54	258		89
Other income (expense), net	(73)		(154)	(20)		(233)
Income before income taxes	8,708		7,716	25,852		22,687
Income tax provision	3,348		3,086	9,798		9,071
Net income	\$ 5,360	\$	4,630 \$	16,054	\$	13,616
Net income per common share:						
Basic	\$ 0.16	\$	0.14 \$	0.49	\$	0.43
Diluted	\$ 0.16	\$	0.14 \$	0.47	\$	0.42
Shares used in computing net income per share:						
Basic	32,771		32,187	32,496		31,920
Diluted	34,566		33,075	34,163		32,667
Cash dividends per share	\$ 0.0200	\$	0.0133 \$	0.0533	\$	0.0267

See notes to condensed consolidated financial statements

Option Care, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

	200	Nine Mon Septem 05	2004
Cash flows from operating activities:			
Net income	\$	16,054	\$ 13,616
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization		4,607	3,542
Provision for doubtful accounts		6,727	4,622
Deferred income taxes		1,244	1,719
Income tax benefit from exercise of stock options		1,973	1,318
Changes in assets and liabilities, net of acquisitions:			
Accounts and notes receivable		(8,450)	(3,746)
Inventory		2,974	1,860
Accounts payable		(4,971)	(2,414)
Income taxes receivable/payable		(273)	3,243
Change in other assets and liabilities		(1,995)	(3,640)
Net cash provided by operating activities		17,890	20,120
Cash flows from investing activities:			
Purchases of short-term investments		(170,840)	
Sales of short-term investments		192,566	
Purchases of equipment and other, net		(7,094)	(4,147)
Payments for acquisitions, net of cash acquired		(46,367)	(3,130)
		(10,201)	(0,000)
Net cash used in investing activities		(31,735)	(7,277)
Cash flows from financing activities			
Cash flows from financing activities: Increase in financing costs		(166)	
Payments on capital leases and other debt		(30)	(393)
Proceeds from issuance of stock		6,060	3,088
Payments of cash dividends to common shareholders		(1,728)	(855)
Payments for purchase of treasury stock		(1,720)	(944)
rayments for purchase of treasury stock			(944)
Net cash provided by financing activities		4,136	896
The easily provided by finalising activities		4,150	070
Net increase (decrease) in cash and cash equivalents		(9,709)	13,739
Cash and cash equivalents, beginning of period		19,816	3,961
Cash and cash equivalents, end of period	\$	10,107	\$ 17,700

See notes to condensed consolidated financial statements

Option Care, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

September 30, 2005

(Unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2005 are not necessarily indicative of the results that may be expected for the year ending December 31, 2005.

The balance sheet at December 31, 2004 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

We completed a 3-for-2 split of our common stock on March 31, 2005 for shareholders of record as of March 17, 2005. All share and per share amounts in this Quarterly Report on Form 10-Q have been adjusted to reflect the pro forma effects of this stock split.

For further information, refer to the consolidated financial statements and footnotes thereto included in Option Care s Annual Report on Form 10-K for the year ended December 31, 2004.

2. Long-Term Debt

On November 2, 2004, we completed a \$75 million offering of 2.25% convertible senior notes due 2024 in a private placement to qualified institutional buyers. The initial purchasers were granted the option to purchase up to an additional \$11.3 million principal amount of notes and exercised this option in full on November 9, 2004. We filed a Registration Statement on Form S-3 with the Securities and Exchange Commission on January 24, 2005 registering the notes and the common stock issuable upon conversion of the notes for resale to the public.

The convertible notes are senior unsecured obligations of Option Care and will be convertible into cash and, if applicable, shares of our common stock based on an initial conversion rate of 55.5278 shares per \$1,000 principal amount of notes, which represents an initial conversion price of \$18.01 per share, subject to adjustment in certain circumstances. The conversion rate and conversion price were subsequently adjusted to 83.3763 and \$11.99 per share, respectively, pursuant to the terms of the notes as a result of our 3-for-2 common stock split on March 31, 2005 and \$0.02 per share dividends paid on June 10, 2005 and September 2, 2005. Note holders may convert their notes into cash and, if applicable,

shares of our common stock prior to the stated maturity only under the following circumstances: (1) during any calendar quarter beginning after December 31, 2004, if the closing sale price of our common stock for each of 20 or more consecutive trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter exceeds 120% of the conversion price in effect on the last trading day of the immediately preceding calendar quarter; (2) during the five business day period after any five consecutive trading day period in which the average trading price per \$1,000 principal amount of notes was equal to or less than 97% of the average conversion value of the notes during the note measurement period; (3) upon the occurrence of specified corporate transactions; or (4) if we have called the notes for redemption. As of September 30, 2005, no triggering event has occurred that would result in the potential conversion of our notes. In general, upon conversion, the holder of each note will receive the conversion value of the note payable in cash, up to the principal amount of the note, and common stock for the notes conversion value in excess of such principal amount (plus an additional cash payout in lieu of fractional shares). If the notes are surrendered for conversion in connection with certain fundamental changes that occur before November 1, 2009, holders will in certain circumstances also receive a make-whole premium in addition to the cash and shares that holders are otherwise entitled to receive upon conversion. The convertible senior notes will mature on November 1, 2024 and will not be redeemable by us prior to November 1, 2009. Holders of the convertible notes may require us to repurchase all or a portion of the convertible notes for cash on November 1, 2009, 2014 and 2019. Interest will be paid at 2.25% per annum, payable semi-annually in arrears on May 1 and November 1 of each year to the holders of record at the close of business on the preceding April 15 and October 15, respectively. The notes are senior unsecured obligations and will rank equally with all of our existing and future senior unsecured indebtedness.

6

3. Earnings Per Share Data

The following table sets forth the computation of basic and diluted earnings per share for the periods indicated. All share and per share amounts reflect the 3-for-2 stock split effective March 31, 2005 for shareholders of record on March 17, 2005. (in thousands, except per share amounts):

	Three months ended September 30,				Nine months ended September 30,			
	2005		2004		2005		2004	
\$	5,360	\$	4,630	\$	16,054	\$	13,616	
	32,771		32,187		32,496		31,920	
\$	0.16	\$	0.14	\$	0.49	\$	0.43	
\$	5,360	\$	4,630	\$	16,054	\$	13,616	
	32,771		32,187		32,496		31,920	
ased on								
	960		888		1,002		747	
vertible								
	835				665			
	34,566		33,075		34,163		32,667	
\$	0.16	\$	0.14	\$	0.47	\$	0.42	
	\$ ased on vertible	Septem 2005 \$ 5,360 32,771 \$ 0.16 \$ 5,360 32,771 ased on 960 vertible 835 34,566	September 30, 2005 S	September 30, 2005 2004 \$ 5,360 \$ 4,630 32,771 32,187 32,187 \$ 0.16 \$ 0.14 \$ 5,360 \$ 4,630 \$ 0.16 \$ 0.14 \$ 5,360 \$ 4,630 \$ 32,771 32,187 ased on 960 888 vertible 835 34,566	September 30, 2005 2004 \$ 5,360 \$ 4,630 \$ \$ 5,360 \$ 4,630 \$ \$ 0.16 \$ 0.14 \$ \$ 5,360 \$ 4,630 \$ \$ 0.16 \$ 0.14 \$ \$ 5,360 \$ 4,630 \$ \$ 32,771 32,187 32,187 ased on 960 888 888 vertible 835 33,075	September 30, 2004 2005 \$ 5,360 \$ 4,630 \$ 16,054 \$ 5,360 \$ 4,630 \$ 16,054 \$ 32,771 32,187 32,496 \$ 0.16 \$ 0.14 \$ 0.49 \$ 5,360 \$ 4,630 \$ 16,054 \$ 0.16 \$ 0.14 \$ 0.49 \$ 5,360 \$ 4,630 \$ 16,054 \$ 32,771 32,187 32,496 32,496 \$ 5,360 \$ 4,630 \$ 16,054 \$ 32,771 32,187 32,496 32,496 ased on 960 888 1,002 960 rettible 835 665 33,075 34,163	September 30, 2005 2004 2005 \$ 5,360 \$ 4,630 \$ 16,054 \$ \$ 5,360 \$ 4,630 \$ 16,054 \$ \$ 32,771 32,187 32,496 \$ \$ 0.49 \$ \$ 0.16 \$ 0.14 \$ 0.49 \$ \$ 5,360 \$ 4,630 \$ 16,054 \$ \$ 5,360 \$ 4,630 \$ 16,054 \$ \$ 5,360 \$ 4,630 \$ 16,054 \$ \$ 32,771 32,187 32,496 \$ ased on 960 888 1,002 \$ rettible 835 665 \$ 34,566 33,075 34,163	

4. **Operating Segments**

We have one identifiable business segment, with three service lines: specialty pharmacy services; infusion and related healthcare services; and other.

Specialty pharmacy services involve the distribution of injectible and infused pharmaceuticals to treat a wide range of chronic health conditions. The pharmaceuticals can be directly distributed to the patient s home or to their physician s office for in-office administration. These pharmaceuticals may require refrigeration during shipping as well as special handling to prevent potency degradation. Patients receiving treatment usually require special counseling and education regarding their condition and treatment program.

Infusion and related healthcare services primarily involve the intravenous administration of medications at the patient s home or other non-hospital sites such as one of our infusion suites. Infusion pharmacy services treat a wide range of acute and chronic health conditions, including infections, dehydration, cancer, pain and nutritional deficiencies. All of our company-owned pharmacies provide infusion pharmacy services. Some of these pharmacies

also provide related healthcare services, such as home health nursing, home hospice services, respiratory therapy services and durable medical equipment.

Other revenue consists of royalties and other fees generated from our franchised pharmacy network, software licensing and support revenue generated by our subsidiary, Management by Information, Inc. (MBI) and other miscellaneous revenue.

5. Significant Customers and Concentration of Credit Risk

We generate the majority of our revenue from managed care contracts and other agreements with commercial third party payors by providing health care services to their members. Our principal managed care contract is with Blue Cross and Blue Shield of Florida, to whose members we provide infusion pharmacy services and specialty pharmacy services. The contract may be terminated by either party on 90 days notice and, unless terminated, renews annually each September for an additional one-year term. We also generate revenue from government healthcare programs such as Medicare and Medicaid.

7

The following table sets forth information regarding revenue and accounts receivable related to our most significant payors as of the dates and for the periods presented:

Revenue									
	Three months		Nine mont		Accounts Receivable				
	September	30,	September 30,		September 30,	December 31,			
	2005	2004	2005	2004	2005	2004			
Blue Cross and Blue Shield of									
Florida	14								